Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018.
Adolescent
Amodiaquine
/ therapeutic use
Antimalarials
/ therapeutic use
Artemether, Lumefantrine Drug Combination
/ therapeutic use
Artemisinins
/ therapeutic use
Child
Child, Preschool
DNA, Protozoan
/ genetics
Drug Combinations
Female
Humans
Infant
Madagascar
/ epidemiology
Malaria, Falciparum
/ drug therapy
Male
Multidrug Resistance-Associated Proteins
/ genetics
Plasmodium falciparum
/ genetics
Polymerase Chain Reaction
Polymorphism, Genetic
Pregnancy
Prevalence
Recurrence
Reinfection
Anti-malarial
Artemisinin-based combination therapy
Efficacy
Madagascar
Resistance
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
03 Nov 2021
03 Nov 2021
Historique:
received:
26
06
2021
accepted:
30
09
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Since 2005, artemisinin-based combination therapy (ACT) has been recommended to treat uncomplicated falciparum malaria in Madagascar. Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first- and second-line treatments, respectively. A therapeutic efficacy study was conducted to assess ACT efficacy and molecular markers of anti-malarial resistance. Children aged six months to 14 years with uncomplicated falciparum malaria and a parasitaemia of 1000-100,000 parasites/µl determined by microscopy were enrolled from May-September 2018 in a 28-day in vivo trial using the 2009 World Health Organization protocol for monitoring anti-malarial efficacy. Participants from two communes, Ankazomborona (tropical, northwest) and Matanga (equatorial, southeast), were randomly assigned to ASAQ or AL arms at their respective sites. PCR correction was achieved by genotyping seven neutral microsatellites in paired pre- and post-treatment samples. Genotyping assays for molecular markers of resistance in the pfk13, pfcrt and pfmdr1 genes were conducted. Of 344 patients enrolled, 167/172 (97%) receiving ASAQ and 168/172 (98%) receiving AL completed the study. For ASAQ, the day-28 cumulative PCR-uncorrected efficacy was 100% (95% CI 100-100) and 95% (95% CI 91-100) for Ankazomborona and Matanga, respectively; for AL, it was 99% (95% CI 97-100) in Ankazomborona and 83% (95% CI 76-92) in Matanga. The day-28 cumulative PCR-corrected efficacy for ASAQ was 100% (95% CI 100-100) and 98% (95% CI 95-100) for Ankazomborona and Matanga, respectively; for AL, it was 100% (95% CI 99-100) in Ankazomborona and 95% (95% CI 91-100) in Matanga. Of 83 successfully sequenced samples for pfk13, no mutation associated with artemisinin resistance was observed. A majority of successfully sequenced samples for pfmdr1 carried either the NFD or NYD haplotypes corresponding to codons 86, 184 and 1246. Of 82 successfully sequenced samples for pfcrt, all were wild type at codons 72-76. PCR-corrected analysis indicated that ASAQ and AL have therapeutic efficacies above the 90% WHO acceptable cut-off. No genetic evidence of resistance to artemisinin was observed, which is consistent with the clinical outcome data. However, the most common pfmdr1 haplotypes were NYD and NFD, previously associated with tolerance to lumefantrine.
Sections du résumé
BACKGROUND
BACKGROUND
Since 2005, artemisinin-based combination therapy (ACT) has been recommended to treat uncomplicated falciparum malaria in Madagascar. Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first- and second-line treatments, respectively. A therapeutic efficacy study was conducted to assess ACT efficacy and molecular markers of anti-malarial resistance.
METHODS
METHODS
Children aged six months to 14 years with uncomplicated falciparum malaria and a parasitaemia of 1000-100,000 parasites/µl determined by microscopy were enrolled from May-September 2018 in a 28-day in vivo trial using the 2009 World Health Organization protocol for monitoring anti-malarial efficacy. Participants from two communes, Ankazomborona (tropical, northwest) and Matanga (equatorial, southeast), were randomly assigned to ASAQ or AL arms at their respective sites. PCR correction was achieved by genotyping seven neutral microsatellites in paired pre- and post-treatment samples. Genotyping assays for molecular markers of resistance in the pfk13, pfcrt and pfmdr1 genes were conducted.
RESULTS
RESULTS
Of 344 patients enrolled, 167/172 (97%) receiving ASAQ and 168/172 (98%) receiving AL completed the study. For ASAQ, the day-28 cumulative PCR-uncorrected efficacy was 100% (95% CI 100-100) and 95% (95% CI 91-100) for Ankazomborona and Matanga, respectively; for AL, it was 99% (95% CI 97-100) in Ankazomborona and 83% (95% CI 76-92) in Matanga. The day-28 cumulative PCR-corrected efficacy for ASAQ was 100% (95% CI 100-100) and 98% (95% CI 95-100) for Ankazomborona and Matanga, respectively; for AL, it was 100% (95% CI 99-100) in Ankazomborona and 95% (95% CI 91-100) in Matanga. Of 83 successfully sequenced samples for pfk13, no mutation associated with artemisinin resistance was observed. A majority of successfully sequenced samples for pfmdr1 carried either the NFD or NYD haplotypes corresponding to codons 86, 184 and 1246. Of 82 successfully sequenced samples for pfcrt, all were wild type at codons 72-76.
CONCLUSION
CONCLUSIONS
PCR-corrected analysis indicated that ASAQ and AL have therapeutic efficacies above the 90% WHO acceptable cut-off. No genetic evidence of resistance to artemisinin was observed, which is consistent with the clinical outcome data. However, the most common pfmdr1 haplotypes were NYD and NFD, previously associated with tolerance to lumefantrine.
Identifiants
pubmed: 34732201
doi: 10.1186/s12936-021-03935-4
pii: 10.1186/s12936-021-03935-4
pmc: PMC8565026
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Artemisinins
0
DNA, Protozoan
0
Drug Combinations
0
Mdr1 protein, Plasmodium falciparum
0
Multidrug Resistance-Associated Proteins
0
amodiaquine, artesunate drug combination
0
Amodiaquine
220236ED28
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
432Informations de copyright
© 2021. The Author(s).
Références
Lancet Infect Dis. 2021 Aug;21(8):1120-1128
pubmed: 33864801
Malar J. 2018 Apr 3;17(1):144
pubmed: 29615039
Lancet. 2012 May 26;379(9830):1960-6
pubmed: 22484134
Antimicrob Agents Chemother. 2009 Nov;53(11):4588-97
pubmed: 19704124
Clin Infect Dis. 2006 Jun 1;42(11):1570-7
pubmed: 16652314
Malar J. 2014 Aug 10;13:309
pubmed: 25108397
Acta Trop. 2005 Jun;94(3):181-90
pubmed: 15876420
PLoS One. 2010 Oct 13;5(10):e13281
pubmed: 20967251
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
J Infect Dis. 2013 Mar 1;207(5):842-7
pubmed: 23225895
N Engl J Med. 2006 Nov 9;355(19):1959-66
pubmed: 17093247
Am J Trop Med Hyg. 2014 Oct;91(4):833-843
pubmed: 25048375
Malar J. 2016 Jan 05;15:6
pubmed: 26728096
Malar J. 2009 Oct 12;8 Suppl 1:S5
pubmed: 19818172
Am J Trop Med Hyg. 2013 Mar;88(3):536-41
pubmed: 23382159
Malar J. 2018 Aug 6;17(1):284
pubmed: 30081916
Antimicrob Agents Chemother. 2015 Oct;59(10):6096-100
pubmed: 26195521
Malar J. 2019 Mar 21;18(1):88
pubmed: 30898164
Acta Trop. 2017 Jul;171:146-150
pubmed: 28373036
Am J Trop Med Hyg. 2006 Nov;75(5):836-42
pubmed: 17123974
PLoS One. 2015 Aug 20;10(8):e0136099
pubmed: 26292024
Antimicrob Agents Chemother. 2021 Jan 20;65(2):
pubmed: 33168604
Trends Parasitol. 2012 Nov;28(11):504-14
pubmed: 23020971
Am J Trop Med Hyg. 2007 Jun;76(6):1079-83
pubmed: 17556614
Trop Med Int Health. 2006 Dec;11(12):1800-7
pubmed: 17176344
J Infect Dis. 2021 Feb 3;223(2):306-309
pubmed: 32594154
Emerg Infect Dis. 2017 Dec;23(13):
pubmed: 29155671
Mol Biol Evol. 2000 Oct;17(10):1467-82
pubmed: 11018154
Malar J. 2017 Feb 2;16(1):62
pubmed: 28153004
Science. 2015 Jan 23;347(6220):428-31
pubmed: 25502314
Eur J Clin Pharmacol. 2008 Jul;64(7):683-90
pubmed: 18415093
Malar J. 2021 Jan 19;20(1):48
pubmed: 33468147